Tokyo, Japan

Hidemi Mizunuma

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Hidemi Mizunuma

Introduction

Hidemi Mizunuma is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of ophthalmology, particularly in the development of therapeutic agents for eye diseases. Her work focuses on addressing critical needs in the treatment of choroidal neovascularization and age-related macular degeneration.

Latest Patents

Mizunuma holds a patent for a "Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same." This invention addresses the limitations of existing therapeutic drugs for choroidal neovascularization (CNV), which are primarily symptomatic treatments. The patent emphasizes the urgent demand for radical cure therapies, particularly for dry age-related macular degeneration (AMD). The invention provides a prophylactic and/or therapeutic agent for CNV, containing a compound that suppresses epithelial-mesenchymal transition in retinal pigment epithelial cells.

Career Highlights

Throughout her career, Mizunuma has worked with notable companies such as Link Genomics, Inc. and Rohto Pharmaceutical Co., Ltd. Her experience in these organizations has contributed to her expertise in developing innovative solutions for eye health.

Collaborations

Mizunuma has collaborated with esteemed colleagues, including Shinichiro Niwa and Dai Ogura. These partnerships have fostered a collaborative environment that enhances the development of her groundbreaking inventions.

Conclusion

Hidemi Mizunuma's contributions to the field of ophthalmology through her innovative patents and collaborations highlight her commitment to advancing therapeutic options for eye diseases. Her work continues to pave the way for future developments in this critical area of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…